{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:05:58Z","timestamp":1794013558511,"version":"4.8.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203312"],"award-info":[{"award-number":["NIHR203312"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Both Crohn\u2019s disease and ulcerative colitis are associated with heterogeneity of presentation, disease course, and outcomes between individuals. The frequency of flares and progression to complications can have a profound impact on quality of life for people living with IBD. Indeed, many patients report suboptimal disease control and major disruption to their lives from active, uncontrolled inflammation. Two major factors potentially contributing to adverse outcomes are delays to establish a diagnosis of IBD and delays in the introduction of effective treatment. Several recent studies have addressed the role of early diagnosis and early treatment, including differences to consider between Crohn\u2019s disease and ulcerative colitis. In this review we summarize the important insights obtained and highlight how outcomes for patients can be improved with a focus on timely diagnosis and timely, effective treatment interventions.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaf203","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:37:59Z","timestamp":1763645879000},"page":"ii3-ii10","source":"Crossref","is-referenced-by-count":9,"title":["Rapid diagnosis and treatment of inflammatory bowel diseases"],"prefix":"10.1093","volume":"20","author":[{"given":"Amit","family":"Thakor","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiumaeswar","family":"Yogakanthi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3426-6408","authenticated-orcid":false,"given":"Nurulamin M","family":"Noor","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["United Kingdom"]},{"name":"Department of Medicine, University of Cambridge School of Clinical Medicine , Cambridge,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Parkes","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["United Kingdom"]},{"name":"Department of Medicine, University of Cambridge School of Clinical Medicine , Cambridge,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026021904202829500_jjaf203-B1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: From 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-025-01097-1","article-title":"The global burden of inflammatory bowel disease: from 2025 to 2045","volume":"22","author":"Kaplan","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"2026021904202829500_jjaf203-B4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.crohns.2014.01.023","article-title":"Diagnostic delay in a French cohort of Crohn\u2019s disease patients","volume":"8","author":"Nahon","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ibd.21719","article-title":"Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease","volume":"18","author":"Vavricka","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026021904202829500_jjaf203-B6","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1097\/MIB.0000000000001257","article-title":"Impact of diagnostic delay and associated factors on clinical outcomes in a U.S. inflammatory bowel disease cohort","volume":"23","author":"Nguyen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026021904202829500_jjaf203-B7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/apt.17370","article-title":"Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease","volume":"57","author":"Jayasooriya","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021904202829500_jjaf203-B8","doi-asserted-by":"crossref","first-page":"101263","DOI":"10.1016\/j.xcrm.2023.101263","article-title":"Characterizing the pre-clinical phase of inflammatory bowel disease","volume":"4","author":"Vestergaard","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026021904202829500_jjaf203-B9","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.3748\/wjg.v30.i29.3465","article-title":"Diagnostic delay in inflammatory bowel diseases in a German population","volume":"30","author":"Bl\u00fcthner","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2026021904202829500_jjaf203-B10","doi-asserted-by":"crossref","first-page":"jjaa146","DOI":"10.1093\/ecco-jcc\/jjaa146","article-title":"Prevalence and duration of gastrointestinal symptoms before diagnosis of inflammatory bowel disease and predictors of timely specialist review: a population-based study","volume":"15","author":"Blackwell","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/2050640614554217","article-title":"Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the general practice research database","volume":"2","author":"Card","year":"2014","journal-title":"United European Gastroenterol J"},{"key":"2026021904202829500_jjaf203-B12","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/ajg.2013.248","article-title":"Diagnostic delay in Crohn\u2019s disease is associated with a complicated disease course and increased operation rate","volume":"108","author":"Schoepfer","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2026021904202829500_jjaf203-B13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/ecco-jcc\/jjv215","article-title":"Diagnostic delay in Romanian patients with inflammatory bowel disease: risk factors and impact on the disease course and need for surgery","volume":"10","author":"Zaharie","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jpedsurg.2019.03.012","article-title":"Diagnostic delay and colectomy risk in pediatric ulcerative colitis","volume":"55","author":"Krishna","year":"2020","journal-title":"J Pediatr Surg"},{"key":"2026021904202829500_jjaf203-B15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ibd\/izae057","article-title":"The time to inflammatory bowel disease diagnosis for patients presenting with abdominal symptoms in primary care and its association with emergency hospital admissions and surgery: a retrospective cohort study","volume":"31","author":"Umar","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026021904202829500_jjaf203-B16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/08870446.2017.1381958","article-title":"A qualitative study exploring the experience of people with IBD and elevated symptoms of anxiety and low mood and the type of psychological help they would like","volume":"33","author":"Jordan","year":"2018","journal-title":"Psychol Health"},{"key":"2026021904202829500_jjaf203-B17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s11136-024-03852-4","article-title":"Understanding diagnostic delays and health outcomes for inflammatory bowel disease: a mixed-methods study of patients\u2019 perspectives","volume":"34","author":"Purc-Stephenson","year":"2025","journal-title":"Qual Life Res"},{"key":"2026021904202829500_jjaf203-B18","doi-asserted-by":"crossref","first-page":"e0301672","DOI":"10.1371\/journal.pone.0301672","article-title":"Sources of diagnostic delay for people with Crohn\u2019s disease and ulcerative colitis: qualitative research study","volume":"19","author":"AWARE-IBD Diagnostic Delay Working Group","year":"2024","journal-title":"PLoS One"},{"key":"2026021904202829500_jjaf203-B19","first-page":"41","article-title":"Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years","volume":"9","author":"Kennedy","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.14563","article-title":"Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with\/without alarm symptoms: a prospective UK primary care cohort study","volume":"47","author":"Walker","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021904202829500_jjaf203-B21","doi-asserted-by":"crossref","first-page":"e044177","DOI":"10.1136\/bmjopen-2020-044177","article-title":"Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the imrd-uk data","volume":"11","author":"Freeman","year":"2021","journal-title":"BMJ Open"},{"key":"2026021904202829500_jjaf203-B22","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/ecco-jcc\/jjaa111","article-title":"Validation of the red flags index for early diagnosis of Crohn\u2019s disease: a prospective observational IG-IBD study among general practitioners","volume":"14","author":"Fiorino","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B23","doi-asserted-by":"crossref","first-page":"e854","DOI":"10.3399\/BJGP.2021.0125","article-title":"Faecal calprotectin testing in UK general practice: a retrospective cohort study using the health improvement network database","volume":"71","author":"Freeman","year":"2021","journal-title":"Br J Gen Pract"},{"key":"2026021904202829500_jjaf203-B24","first-page":"S74","article-title":"Early inflammatory clinics. Experience with early arthritis\/back pain clinics","volume":"27","author":"Go\u00ebb","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2026021904202829500_jjaf203-B25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/flgastro-2021-102047","article-title":"Impact of direct-access IBD physician delivered endoscopy on clinical outcomes: a pre-implementation and post-implementation study","volume":"13","author":"Stammers","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"2026021904202829500_jjaf203-B26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S2468-1253(24)00350-9","article-title":"Primary care diagnostic pathways for lower gastrointestinal symptoms","volume":"10","author":"Din","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1053\/j.gastro.2025.08.007","article-title":"Navigating the differential diagnosis of intestinal tuberculosis and Crohn\u2019s disease","volume":"169","author":"Pratap Mouli","year":"2025","journal-title":"Gastroenterology"},{"key":"2026021904202829500_jjaf203-B28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/flgastro-2023-102409","article-title":"Establishing key performance indicators for inflammatory bowel disease in the UK","volume":"14","author":"Quraishi","year":"2023","journal-title":"Frontline Gastroenterol"},{"key":"2026021904202829500_jjaf203-B29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ecco-jcc\/jjaa023","article-title":"Quality of care standards in Inflammatory Bowel Diseases: a European Crohn\u2019s and Colitis Organisation [ECCO] position paper","volume":"14","author":"Fiorino","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B30","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/apt.18294","article-title":"Review article: novel therapies in inflammatory bowel disease\u2014an update for clinicians","volume":"60","author":"Noor","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021904202829500_jjaf203-B31","doi-asserted-by":"crossref","first-page":"otae040","DOI":"10.1093\/crocol\/otae040","article-title":"Treatment pathways in patients with Crohn\u2019s disease and ulcerative colitis: understanding the road to advanced therapy","volume":"6","author":"Siegel","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"2026021904202829500_jjaf203-B32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ueg2.12572","article-title":"Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-real-world evidence from the inflammatory bowel diseases-podcast study","volume":"12","author":"D\u2019Amico","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2026021904202829500_jjaf203-B33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41575-024-00935-y","article-title":"A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn\u2019s disease in clinical practice","volume":"21","author":"Bettenworth","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B34","first-page":"35","article-title":"Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier","volume":"236","author":"Yiu","year":"2022","journal-title":"Trans Res"},{"key":"2026021904202829500_jjaf203-B35","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/S1873-9946(12)60502-9","article-title":"Changing Crohn\u2019s disease management: need for new goals and indices to prevent disability and improve quality of life","volume":"6 Suppl 2","author":"Hommes","year":"2012","journal-title":"J Crohns Colitis."},{"key":"2026021904202829500_jjaf203-B36","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn\u2019s disease digestive damage score, the L\u00e9mann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026021904202829500_jjaf203-B37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn\u2019s disease","volume":"7","author":"Schreiber","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator na\u00efve patients with Crohn\u2019s disease\u2014a SONIC post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021904202829500_jjaf203-B39","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"2026021904202829500_jjaf203-B40","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/ibd\/izaa031","article-title":"Early vs late use of anti-TNFa therapy in adult patients with Crohn disease: a systematic review and meta-analysis","volume":"26","author":"Hamdeh","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026021904202829500_jjaf203-B41","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn\u2019s disease","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021904202829500_jjaf203-B42","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cgh.2024.07.034","article-title":"Early biological therapy within 12 months of diagnosis leads to higher transmural healing rates in Crohn\u2019s disease","volume":"23","author":"Rev\u00e9s","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.berh.2006.05.005","article-title":"Treating very early rheumatoid arthritis","volume":"20","author":"Raza","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026021904202829500_jjaf203-B44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn\u2019s disease: an open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut"},{"key":"2026021904202829500_jjaf203-B46","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/gutjnl-2024-333280","article-title":"Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn\u2019s disease: post hoc analysis of the risk study","volume":"74","author":"Adler","year":"2025","journal-title":"Gut"},{"key":"2026021904202829500_jjaf203-B47","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the treat\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2026021904202829500_jjaf203-B48","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.cgh.2024.01.003","article-title":"Impact of treatment response on risk of serious infections in patients with Crohn\u2019s disease: Secondary analysis of the pyramid registry","volume":"22","author":"Ahuja","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B49","doi-asserted-by":"crossref","first-page":"jjaf150","DOI":"10.1093\/ecco-jcc\/jjaf150","article-title":"Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional \"step-up\" care for patients with active Crohn\u2019s disease: a cost-effectiveness analysis from the profile trial","volume":"19","author":"Noor","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B50","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/apt.18000","article-title":"Randomised clinical trial: first-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn\u2019s disease","volume":"59","author":"Vuijk","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021904202829500_jjaf203-B51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2468-1253(25)00233-X","article-title":"Vedolizumab in early and late Crohn\u2019s disease (LOVE-CD): a phase 4 open-label cohort study","volume":"11","author":"D\u2019Haens","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B52","doi-asserted-by":"crossref","first-page":"i1470","DOI":"10.1093\/ecco-jcc\/jjae190.0936","article-title":"P0762 early ustekinumab use improves clinical outcomes in biologic-naive Crohn\u2019s disease patients: A retrospective multicenter cohort study in taiwan","volume":"19","author":"Chang","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B53","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.gastha.2024.02.008","article-title":"Shorter Crohn\u2019s disease duration is associated with better clinical and endoscopic outcomes with risankizumab in phase 3 studies","volume":"3","author":"Peyrin-Biroulet","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"2026021904202829500_jjaf203-B54","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","article-title":"Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials","volume":"162","author":"Ben-Horin","year":"2022","journal-title":"Gastroenterology"},{"key":"2026021904202829500_jjaf203-B55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3349\/ymj.2020.61.5.382","article-title":"Similar clinical outcomes of early and late anti-TNF initiation for ulcerative colitis: a nationwide population-based study","volume":"61","author":"Han","year":"2020","journal-title":"Yonsei Med J"},{"key":"2026021904202829500_jjaf203-B56","first-page":"2079582","article-title":"Similar clinical and surgical outcomes achieved with early compared to late anti-TNF induction in mild-to-moderate ulcerative colitis: a retrospective cohort study","volume":"2016","author":"Ma","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2026021904202829500_jjaf203-B57","doi-asserted-by":"crossref","first-page":"otae061","DOI":"10.1093\/crocol\/otae061","article-title":"Real-world treatment outcomes associated with early versus delayed vedolizumab initiation in patients with ulcerative colitis","volume":"6","author":"Krugliak Cleveland","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"2026021904202829500_jjaf203-B58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10 years of ulcerative colitis: Results from a population-based inception cohort (IBSEN study)","volume":"44","author":"Solberg","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"2026021904202829500_jjaf203-B59","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ecco-jcc\/jjaa232","article-title":"Outcome of ulcerative colitis 20 years after diagnosis in a prospective population-based inception cohort from south-eastern Norway, the IBSEN study","volume":"15","author":"Monstad","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026021904202829500_jjaf203-B60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/gutjnl-2019-320185","article-title":"Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn\u2019s disease: Long-term outcomes for 11\u2009928 patients in the UK inflammatory bowel disease bioresource","volume":"70","author":"Stournaras","year":"2021","journal-title":"Gut"},{"key":"2026021904202829500_jjaf203-B61","first-page":"Cd008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021904202829500_jjaf203-B62","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026021904202829500_jjaf203-B63","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s10620-011-1877-6","article-title":"Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database","volume":"56","author":"Kane","year":"2011","journal-title":"Dig Dis Sci"},{"key":"2026021904202829500_jjaf203-B64","doi-asserted-by":"crossref","first-page":"e001218","DOI":"10.1136\/bmjgast-2023-001218","article-title":"Determining the optimal treatment target in patients with ulcerative colitis: Rationale, design, protocol and interim analysis for the randomised controlled verdict trial","volume":"11","author":"Jairath","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"2026021904202829500_jjaf203-B65","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/gutjnl-2017-314190","article-title":"Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study","volume":"68","author":"Choi","year":"2019","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/Supplement_2\/ii3\/66988375\/jjaf203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/Supplement_2\/ii3\/66988375\/jjaf203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:23:43Z","timestamp":1771493023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/20\/Supplement_2\/ii3\/8489898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":65,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf203","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2,1]]}}}